Avai BioAVAI +3.24%24 Equity-to-Asset is -16.15 as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,883 Software companies, Avai Bio ranks worse than 98.86% on this metric.
Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Avai Bio's Total Stockholders Equity for the quarter that ended in Dec. 2025 was $-2.79 Mil. Avai Bio's Total Assets for the quarter that ended in Dec. 2025 was $0.17 Mil.
The historical rank and industry rank for Avai Bio's Equity-to-Asset or its related term are showing as below:
AVAI'
s Equity-to-Asset Range Over the Past 10 Years
Min: -16.15 Med: -1.61 Max: 0.38
Current: -16.15
During the past 8 years, the highest Equity to Asset Ratio of Avai Bio was 0.38. The lowest was -16.15. And the median was -1.61.
AVAI's Equity-to-Asset is ranked worse than 98.86% of 2883
companies
in the Software industry
Industry Median: 0.56
vs AVAI: -16.15
Avai Bio (OTCPK:AVAI) Equity-to-Asset Explanation
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Avai Bio Equity-to-Asset Related Terms
Avai Bio Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Avai Bio's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVAI vs IPM, RCT, LPSN: Equity-to-Asset Comparison
For the Software - Application subindustry, Avai Bio's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio Equity-to-Asset vs Software Industry
For the Software industry and Technology sector, Avai Bio's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Avai Bio's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Avai Bio's Equity to Asset Ratio for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a Equity-to-Asset of -16.15 as of Dec. 2025. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #2850 out of 2883 companies in the Software industry, placing it in the top 98.9%.
Is Avai Bio's Equity-to-Asset too high?
Avai Bio's current Equity-to-Asset is -16.15. Based on the distribution chart, Avai Bio ranks #2850 out of 2883 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Equity-to-Asset compare to IPM and RCT?
According to the Software industry distribution chart, Avai Bio ranks #2850 out of 2883 companies for Equity-to-Asset. This places Avai Bio in the lower half of its industry. The industry median Equity-to-Asset is 0.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Software company?
The median Equity-to-Asset among Software companies is 0.56, based on 2,883 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Avai Bio and its competitors. For the Software industry, the median Equity-to-Asset is 0.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Equity-to-Asset is -16.15. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Equity-to-Asset of -16.15. The current Equity-to-Asset is -16.15. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Avai Bio (AVAI), the current Equity-to-Asset is -16.15 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
